New technology developed at BC Cancer Agency may revolutionize radiation therapy delivery

The Agency developed a revolutionary technology called Volumetric Modulated Arc Therapy (VMAT) that will enable cancer patients to receive faster and more precise radiation therapy through a single 360-degree rotation of the radiation beam around the body. VMAT involves an innovative method for manipulating the radiation beams that can be delivered from a standard linear accelerator (a machine...

Smoking causes irreversible gene damage

Researchers discovered new evidence that explained why former smokers are still susceptible to lung cancer after they have stopped smoking for many years. The study showed that in former smokers, some genes return to levels similar to people who never smoked, while other genes appear to be permanently damaged

Stem cell subtypes discovered by BC Cancer Agency

Researchers discovered that there are distinct subtypes of blood stem cells. Each stem cell behaves uniquely and produces different types of mature blood cells in a transplant setting. This may lead to improved treatments for leukemia patients.

BC Cancer Agency scientists discover new gene that suppresses tumour growth

Researchers discovered a novel gene, HACE1, which suppresses the growth of human tumours in multiple cancers including breast, lung and liver cancers as well as melanomas, lymphomas and sarcomas. The discovery of this gene clearly impacts a wide range of cancers, and provides a novel link between cellular stress and cancer with a potential to improve treatments for many cancer patients.

BC Cancer Agency study tests value of online emotional support

The Agency launched the first-of-its-kind study in Canada to test the value of online emotional support in improving the quality of life of young women with breast cancer. The study will investigate whether the online skills and support group can reduce distress, change perception of how much breast cancer interferes with the physical well-being, and increase participants’ confidence in coping...

Gene mutation lets leukemia fight drug that helps remission

Researchers at the BC Cancer Agency’s Terry Fox Laboratory discovered that chronic myeloid leukemia (CML) stem cells spontaneously develop resistance to Gleevec, possibly due to continuing genetic mutations. Gleevec is an oral chemotherapy drug that helps reduce the symptoms of CML and allows patients to return to a normal life.

Pages